Pfizer ($PFE) is working with Akili Interactive Labs on a video game app designed to diagnose Alzheimer's. The game attempts to assess whether someone has Alzheimer's by evaluating how well they respond to distractions and interruptions. Pfizer is now trialing the system by having 100 healthy patients, some of whom have Alzheimer's-tied amyloid proteins in their brains, use the game. If successful, the game could become a biomarker or endpoint in future trials. Article